贝达药业：国内业绩加速增长，海外布局逐渐兑现

Investment Rating - The report maintains a "Buy-A" investment rating for the company [5]. Core Views - The company has shown accelerated domestic performance with a revenue of 2.345 billion yuan in the first three quarters of 2024, representing a year-on-year growth of 14.73%. The net profit attributable to shareholders reached 416 million yuan, up 36.61% year-on-year [1]. - The company is experiencing rapid growth in its domestic products, including Beifu, Ensat, and Voronib, with potential new approvals expected next year. The third-generation EGFR TKI Beifu is participating in this year's medical insurance negotiations, which could significantly boost sales in 2025 if included in the insurance directory [2]. - The overseas expansion is beginning to yield results, with Ensat expected to receive FDA approval by the end of 2024. The eye drug EYP-1901 has entered Phase 3 clinical trials overseas, indicating promising future developments [3]. Financial Projections - Revenue growth is projected at 24.8%, 23.5%, and 22.6% for 2024 to 2026, respectively. Net profit growth is expected to be 47.7%, 41.6%, and 26.9% for the same period. Corresponding EPS is forecasted to be 1.23 yuan, 1.74 yuan, and 2.21 yuan, with PE ratios of 39.0x, 27.6x, and 21.7x [4][8]. - The target price for the stock is set at 60.90 yuan per share, based on a 35x PE valuation for 2025 [4]. Market Performance - The company's stock has shown a relative performance with a 12-month price range of 30.78 to 61.65 yuan, and a market capitalization of approximately 20.07 billion yuan [5][6]. Clinical Pipeline - The company has a robust clinical pipeline with several products in various stages of development, including ongoing clinical trials for Ensat and the CDK4/6 inhibitor Tai Beisi Li, which is expected to be approved next year [2][3]. Summary of Financial Metrics - The company reported a net profit of 145.4 million yuan in 2022, with projections of 348 million yuan for 2023 and 514.1 million yuan for 2024, indicating strong growth potential [8][9]. - The gross profit margin is expected to remain stable, with a projected net profit margin of 16.8% in 2024, increasing to 19.9% by 2026 [8]. Conclusion - The report highlights the company's strong growth trajectory, promising product pipeline, and favorable market conditions, supporting the "Buy-A" investment rating and a positive outlook for future performance [4][5][6].